Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG …,

The trial is a Phase 3 randomized, controlled, open-label, multicenter clinical trial, aiming to evaluate the efficacy and safety of ATG-010, bortezomib and …, The trial is a Phase 3 randomized, controlled, open-label, multicenter clinical trial, aiming to evaluate the efficacy and safety of ATG-010, bortezomib and …, Read More

Scroll to Top